Premium
Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry
Author(s) -
Isabel Padrão Ana,
Ferreira Rita,
Vitorino Rui,
Amado Francisco
Publication year - 2012
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201200044
Subject(s) - proteomics , diabetes mellitus , proteome , medicine , identification (biology) , disease , omics , bioinformatics , computational biology , intensive care medicine , biology , endocrinology , biochemistry , botany , gene
The worldwide number of individuals suffering from diabetes mellitus ( DM ) has been projected to rise from 171 million in 2000 to 366 million in 2030. Identification of specific biomarkers for prediction and monitoring of DM is needed not only for the adequate screening diagnosis but also to assist the design of interventions to prevent or delay progression of this pathology and its attendant complications. Proteomic methods based on MS hold special promise for the identification of novel biomarkers that might form the foundation for new clinical tests, but to date, their contribution has been somehow unfruitful. Indeed, from more than 300 proteins found differently modulated in body fluids from diabetic patients, approximately 50 were validated with other approaches like ELISA or W estern blotting and the clinical trials are being initiated to employ biofluids’ proteomics (specifically urinary proteomics) in clinical decision. This review provides an overview of MS ‐based applications in the identification of potential biomarkers for DM , emphasizing the methodological challenges involved.